RNA Interference – Talk Bio

Novartis Again Partners with Argo Biopharma in $5.2B+ RNAi Cardiovascular Deal

2 weeks ago talkbio0Tagged ANGPTL3, Biopharma, biotech collaboration, cardiovascular pipeline, Drug Development, Dyslipidemias, milestone payments, Novartis, RNA Interference, RNA, Small Interfering

Novartis; Argo Biopharma; RNA interference (RNAi); siRNA; cardiovascular pipeline; ANGPTL3; dyslipidemia; biotech collaboration; drug development; milestone payments

Novartis Takes Another Shot at Alpha-Synuclein With $2.2B Arrowhead CNS Deal

2 weeks ago talkbio0Tagged alpha-Synuclein, ARO-SNCA, Arrowhead Pharmaceuticals, biotech partnerships, Gene Silencing, Nerve Degeneration, Novartis, Parkinson 's disease, RNA Interference, TRiM platform

Novartis; Arrowhead Pharmaceuticals; alpha-synuclein; Parkinson’s disease; RNA interference (RNAi); gene silencing; ARO-SNCA; TRiM platform; neurodegeneration; biotech partnerships

Roche and Alnylam Push Zilebesiran into Phase III Trial Despite Mixed Phase II Hypertension Data

2 weeks ago talkbio0Tagged Alnylam, Cardiovascular system, Hypertensive disease, KARDIA-3, outcomes, Phase 2 Clinical Trials, Phase 3 Clinical Trials, RNA Interference, Roche (company), ZENITH trial, Zilebesiran

Roche; Alnylam; zilebesiran; hypertension; RNAi therapeutics; KARDIA-3; Phase II trial; Phase III trial; cardiovascular outcomes; ZENITH trial

Sarepta Sells $174 Million Stake in Arrowhead to Fund Milestone Payment Amid Cash Crunch

1 month ago talkbio0Tagged Arrowhead, Cash Crunch, Collaboration, milestone payment, Myotonic Dystrophy, private block trade, RNA Interference, SRP-1003, stake sale

Sarepta Therapeutics; Arrowhead Pharmaceuticals; cash crunch; stake sale; milestone payment; RNAi collaboration; SRP-1003; myotonic dystrophy; private block trade

Sanofi Acquires China Rights to Arrowhead’s Plozasiran for $395 Million

1 month ago talkbio0Tagged Arrowhead, China, Familial chylomicronemia syndrome, Hypertriglyceridemia, milestone payments, Partnership, Plozasiran, RNA Interference, sanofi, Severe (severity modifier)

Sanofi; Arrowhead Pharmaceuticals; Visirna Therapeutics; Plozasiran; China rights; RNA interference; Familial chylomicronemia syndrome; Severe hypertriglyceridemia; biotech partnership; milestone payments

Alnylam’s Amvuttra Approved for ATTR Cardiomyopathy, Challenging Pfizer and BridgeBio

6 months ago talkbio0Tagged Amvuttra, Approved, ATTR-CM, Cardiomyopathies, RNA Interference, United States Food and Drug Administration

Amvuttra, vutrisiran, ATTR-CM, FDA approval, RNAi therapeutic, cardiomyopathy

Arrowhead finds RNAi kidney disease candidate is well tolerated in phase 1/2 IgAN trial cohort

6 months ago talkbio0Tagged ARO-C3, IGA Glomerulonephritis, RNA Interference

ARO-C3, IGA Glomerulonephritis, RNA Interference

Bausch + Lomb Collaborates with City Therapeutics on Novel RNAi-Based Treatment for Geographic Atrophy

8 months ago talkbio0Tagged Age related macular degeneration, Bausch, Cities, Geographic Atrophy, Lomb, Ophthalmologic diseases, RNA Interference, strategic collaboration

Bausch + Lomb, City Therapeutics, RNA interference (RNAi), Geographic atrophy (GA), Age-related macular degeneration (AMD), Strategic collaboration, Ophthalmologic diseases